234 related articles for article (PubMed ID: 36228738)
21. Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.
Zhang W; Chen X; Gao G; Xing S; Zhou L; Tang X; Zhao X; An Y
Front Immunol; 2021; 12():654406. PubMed ID: 33777053
[No Abstract] [Full Text] [Related]
22. STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases.
Lorenzini T; Dotta L; Giacomelli M; Vairo D; Badolato R
J Leukoc Biol; 2017 Jan; 101(1):29-38. PubMed ID: 27803128
[TBL] [Abstract][Full Text] [Related]
23. Dysregulated IFN-γ signals promote autoimmunity in STAT1 gain-of-function syndrome.
Largent AD; Lambert K; Chiang K; Shumlak N; Liggitt D; Oukka M; Torgerson TR; Buckner JH; Allenspach EJ; Rawlings DJ; Jackson SW
Sci Transl Med; 2023 Jul; 15(703):eade7028. PubMed ID: 37406138
[TBL] [Abstract][Full Text] [Related]
24. Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a STAT3 Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?
.
Sediva H; Dusatkova P; Kanderova V; Obermannova B; Kayserova J; Sramkova L; Zemkova D; Elblova L; Svaton M; Zachova R; Kolouskova S; Fronkova E; Sumnik Z; Sediva A; Lebl J; Pruhova S
Horm Res Paediatr; 2017; 88(2):160-166. PubMed ID: 28253502
[TBL] [Abstract][Full Text] [Related]
25. Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations.
Gutiérrez M; Scaglia P; Keselman A; Martucci L; Karabatas L; Domené S; Martin A; Pennisi P; Blanco M; Sanguineti N; Bezrodnik L; Di Giovanni D; Caldirola MS; Azcoiti ME; Gaillard MI; Denson LA; Zhang K; Husami A; Yayah Jones NH; Hwa V; Revale S; Vázquez M; Jasper H; Kumar A; Domené H
Mol Cell Endocrinol; 2018 Sep; 473():166-177. PubMed ID: 29378236
[TBL] [Abstract][Full Text] [Related]
26. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3.
Haapaniemi EM; Kaustio M; Rajala HL; van Adrichem AJ; Kainulainen L; Glumoff V; Doffinger R; Kuusanmäki H; Heiskanen-Kosma T; Trotta L; Chiang S; Kulmala P; Eldfors S; Katainen R; Siitonen S; Karjalainen-Lindsberg ML; Kovanen PE; Otonkoski T; Porkka K; Heiskanen K; Hänninen A; Bryceson YT; Uusitalo-Seppälä R; Saarela J; Seppänen M; Mustjoki S; Kere J
Blood; 2015 Jan; 125(4):639-48. PubMed ID: 25349174
[TBL] [Abstract][Full Text] [Related]
27. Case Report: Signal Transducer and Activator of Transcription 3 Gain-of-Function and Spectrin Deficiency: A Life-Threatening Case of Severe Hemolytic Anemia.
Ciullini Mannurita S; Goda R; Schiavo E; Coniglio ML; Azzali A; Fotzi I; Tondo A; Tintori V; Frenos S; Sanvito MC; Vignoli M; Luceri C; Bigagli E; Grassi A; D'Elios MM; Favre C; Gambineri E
Front Immunol; 2020; 11():620046. PubMed ID: 33519826
[No Abstract] [Full Text] [Related]
28. The ups and downs of STAT3 function: too much, too little and human immune dysregulation.
Mackie J; Ma CS; Tangye SG; Guerin A
Clin Exp Immunol; 2023 Apr; 212(2):107-116. PubMed ID: 36652220
[TBL] [Abstract][Full Text] [Related]
29. Janus kinase inhibitors ameliorate clinical symptoms in patients with STAT3 gain-of-function.
Kaneko S; Sakura F; Tanita K; Shimbo A; Nambu R; Yoshida M; Umetsu S; Inui A; Okada C; Tsumura M; Yamada M; Suzuki H; Kosaki K; Ohara O; Shimizu M; Morio T; Okada S; Kanegane H
Immunother Adv; 2023; 3(1):ltad027. PubMed ID: 38549698
[TBL] [Abstract][Full Text] [Related]
30. Autoimmunity in monogenic combined immune deficiencies with associated or syndromic features.
Sharifinejad N; Azizi G; Chavoshzadeh Z; Mahdaviani SA; Alan MS; Tavakol M; Sadri H; Nabavi M; Ebrahimi SS; Shirkani A; Vosughi Motlagh A; Safarirad M; Aghamahdi F; Nazari F; Delavari S; Jamee M; Fayyaz F; Samimisedeh P; Matani R; Esmaeili M; Yazdani R; Rezaei N; Abolhassani H
Front Immunol; 2022; 13():1023127. PubMed ID: 36544766
[TBL] [Abstract][Full Text] [Related]
31. Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
López-Nevado M; González-Granado LI; Ruiz-García R; Pleguezuelo D; Cabrera-Marante O; Salmón N; Blanco-Lobo P; Domínguez-Pinilla N; Rodríguez-Pena R; Sebastián E; Cruz-Rojo J; Olbrich P; Ruiz-Contreras J; Paz-Artal E; Neth O; Allende LM
Front Immunol; 2021; 12():671755. PubMed ID: 34447369
[TBL] [Abstract][Full Text] [Related]
32. Precision medicine in the treatment of primary immunodeficiency diseases.
Leiding JW; Ballow M
Curr Opin Allergy Clin Immunol; 2018 Apr; 18(2):159-166. PubMed ID: 29406361
[TBL] [Abstract][Full Text] [Related]
33. The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.
Kelaidi C; Tzotzola V; Polychronopoulou S
Fam Cancer; 2021 Oct; 20(4):363-380. PubMed ID: 34128135
[TBL] [Abstract][Full Text] [Related]
34. [; CLINICAL CASE OF STAT3 GOF IMMUNE DYSREGULATION DISEASE, ALPS].
Ussenova O; Morenko M; Kovzel E; Schnaider K; Vlashenyuk K
Georgian Med News; 2020; (304-305):100-103. PubMed ID: 32965258
[TBL] [Abstract][Full Text] [Related]
35. Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1.
Baris S; Alroqi F; Kiykim A; Karakoc-Aydiner E; Ogulur I; Ozen A; Charbonnier LM; Bakır M; Boztug K; Chatila TA; Barlan IB
J Clin Immunol; 2016 Oct; 36(7):641-8. PubMed ID: 27379765
[TBL] [Abstract][Full Text] [Related]
36. Activation of gp130 signaling in T cells drives T
Baumgartner F; Bamopoulos SA; Faletti L; Hsiao HJ; Holz M; Gonzalez-Menendez I; Solé-Boldo L; Horne A; Gosavi S; Özerdem C; Singh N; Liebig S; Ramamoorthy S; Lehmann M; Demel U; Kühl AA; Wartewig T; Ruland J; Wunderlich FT; Schick M; Walther W; Rose-John S; Haas S; Quintanilla-Martinez L; Feske S; Ehl S; Glauben R; Keller U
Sci Signal; 2024 Feb; 17(824):eadc9662. PubMed ID: 38377177
[TBL] [Abstract][Full Text] [Related]
37. Human T
Zhang Y; Siegel AM; Sun G; Dimaggio T; Freeman AF; Milner JD
J Allergy Clin Immunol; 2019 Mar; 143(3):1108-1118.e4. PubMed ID: 30030006
[TBL] [Abstract][Full Text] [Related]
38. The Ying and Yang of STAT3 in Human Disease.
Vogel TP; Milner JD; Cooper MA
J Clin Immunol; 2015 Oct; 35(7):615-23. PubMed ID: 26280891
[TBL] [Abstract][Full Text] [Related]
39. STAT3 Gain-of-Function Mutations Underlie Deficiency in Human Nonclassical CD16
Korenfeld D; Roussak K; Dinkel S; Vogel TP; Pollack H; Levy J; Leiding JW; Milner J; Cooper M; Klechevsky E
J Immunol; 2021 Nov; 207(10):2423-2432. PubMed ID: 34654687
[TBL] [Abstract][Full Text] [Related]
40. Signal transducer and activator of transcription 3: a year in review.
Forbes LR; Milner J; Haddad E
Curr Opin Hematol; 2016 Jan; 23(1):23-7. PubMed ID: 26574998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
